Annals of Oncology

AI summary · may contain errors

Adjuvant pembrolizumab after surgery in high-recurrence clear cell renal cell carcinoma shows sustained disease-free survival benefit (HR 0.71) and improved overall survival (HR 0.66) at 5 years.

AI summary · may contain errors

In previously untreated advanced esophageal squamous cell carcinoma with tumor cell PD-L1 ≥1%, nivolumab plus chemotherapy or nivolumab plus ipilimumab improved overall survival at 5 years (HR 0.62 for both).

AI summary · may contain errors

Enzalutamide plus testosterone suppression improved overall survival versus a first-generation nonsteroidal antiandrogen in metastatic hormone-sensitive prostate cancer, with 8-year OS 50% vs 40% (HR 0.73).

AI summary · may contain errors

In the OlympiA phase III trial of 1836 women with germline BRCA1/BRCA2-associated high-risk HER2-negative early breast cancer, 1-year adjuvant olaparib maintained survival benefits at 6.1 years.

AI summary · may contain errors

Iza-bren (BL-B01D1) showed clinically meaningful antitumor activity in heavily pretreated metastatic breast cancer, with confirmed objective response rates of 46.3% in HER2-positive patients.

AI summary · may contain errors

Perioperative pembrolizumab added to neoadjuvant platinum-doublet chemotherapy nearly doubled 5-year event-free survival in resectable stage II–IIIB (N2) NSCLC, reaching 49.9% vs 26.5%.

AI summary · may contain errors

In stage III, unresectable PD-L1–positive NSCLC after platinum-based concurrent chemoradiation, tiragolumab plus atezolizumab did not improve IRF-assessed PFS (19.4 vs 16.6 months).

AI summary · may contain errors

RAS alterations mediate resistance in about 10% of oncogene-driven lung cancer patients, with KRAS G12D enriched among cases progressing on osimertinib.

AI summary · may contain errors

Atezolizumab plus tiragolumab after definitive chemoradiotherapy in unresectable ESCC did not significantly improve investigator-assessed progression-free survival (HR 0.82, P=0.0947).

AI summary · may contain errors

In TRAK-ER early high-risk ER-positive, HER2-negative breast cancer, ctDNA is detected in 5.0% at the first test and 23.7% cumulatively by 5 years post-surgery.

AI summary · may contain errors

In previously treated locally recurrent or metastatic triple-negative breast cancer, sacituzumab tirumotecan improved overall survival versus chemotherapy, with median OS 14.7 vs 9.9 months (HR 0.60).

AI summary · may contain errors

Perioperative toripalimab plus chemotherapy improved investigator-assessed event-free survival in resectable stage II/III non-small-cell lung cancer, with stratified HR 0.52 at final analysis.

AI summary · may contain errors

Extended follow-up in patients with small-cell lung cancer shows tarlatamab improves median overall survival to 13.6 months versus 8.4 with chemotherapy.

AI summary · may contain errors

Risvutatug rezetecan improved BICR-assessed progression-free survival versus gemcitabine-docetaxel in Chinese patients with relapsed or refractory osteosarcoma, with median 5.5 vs 1.4 months (HR 0.33).

AI summary · may contain errors

In treatment-naïve stage IV or unresectable stage III NSCLC with PD-L1 ≥50%, adding platinum chemotherapy to pembrolizumab significantly improved median progression-free survival to 16.1 months vs 6.9.

AI summary · may contain errors

In high-risk stage III colon adenocarcinoma (pT4 and/or pN2) after R0 resection, adjuvant mFOLFIRINOX did not improve 3-year disease-free survival versus mFOLFOX6 (65.6% vs 66.3%).

AI summary · may contain errors

Adding belzutifan or quavonlimab to pembrolizumab plus lenvatinib in previously untreated advanced clear-cell renal-cell carcinoma did not improve PFS or OS.

AI summary · may contain errors

Belzutifan plus lenvatinib improved progression-free survival in advanced clear-cell renal-cell carcinoma after anti-PD-(L)1 therapy, with HR 0.74 at final LITESPARK-011 analysis.

AI summary · may contain errors

Dostarlimab monotherapy in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer achieved 68% sustained clinical complete response at 12 months (cCR12, investigator review).

AI summary · may contain errors

Abemaciclib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer after progression on prior CDK4/6 inhibitor plus endocrine therapy showed numerically longer overall survival (32.1 vs 24.6 months; HR 0.80).

AI summary · may contain errors

In advanced metastatic colorectal cancer, Temab-A 2.4 mg/kg plus bevacizumab achieved a 30% objective response rate and improved progression-free survival versus trifluridine-tipiracil plus bevacizumab.

AI summary · may contain errors

Pembrolizumab plus chemotherapy improved progression-free survival versus placebo plus chemotherapy in PD-L1–positive (CPS ≥1) HR+/HER2− advanced breast cancer, with PFS HR 0.74.

AI summary · may contain errors

Cisplatin plus gemcitabine in the adjuvant setting for resected biliary tract cancer did not statistically improve disease-free survival versus capecitabine (25.7 vs 17.9 months).